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Attenuated immunogenic parasites are essential in the transfer of immunity to 
virulent Plasmodium berghei
C. M . C E L L U Z Z I, P. L. L IE M , TH  V A N  D E W IE L  & W. M. C. E L IN G  Department of Medical Parasitology,
Faculty o f Medicine, Catholic University o f Nijmegen, the Netherlands
SU M M A R Y
A less virulent parasite of Plasmodium berghei K173 was isolated that induced immunity against 
the m ore virulent parasite. Immunity to this parasite but not to the virulent one, could be 
transferred by immune spleen cells but not by immune lymph node cells. However, the immune 
spleen cells did transfer immunity to the virulent strain if  accompanied by infection with viable 
parasites of the less virulent strain, but only if they were allowed to proliferate for a period o f 
1 week before challenge with the virulent strain. Immune spleen ceils could survive two cycles of 
mouse to mouse transfer. The induction of immunity by transfer of immune spleen cells was 
associated with the production of anti-parasitic antibody.
IN T R O D U C T IO N
To induce immunity against the malaria parasite Plasmodium, 
several immunization procedures have been employed using 
parasites with self-resolving infections1"3 or parasites that have 
been administered under chemotherapeutic control,4“8 to allow 
the parasite to be maintained at appropriate levels capable of 
stimulating the immune system without totally overwhelming 
it.
One such immunization procedure employed in this 
laboratory involved the injection o f 1-3 x 107 virulent 
Plasmodium berghei (K173) parasites and the application of 
sulphonamides for 5 weeks.7 After this time, mice were able to 
control a new challenge with the parasite. It appeared that the 
persistence o f the live parasite during the 5-week immunization 
period was im portant for development of immunity.6,7,9-11 In 
addition, immunosuppressive measures preventing induction of 
immunity were particularly effective in the last week of the 5- 
week immunization period .12,13 This suggested that during the 
last part of the immunization period specific changes occurred 
in the host-parasite  interaction, By transfer of spleen cells or 
blood of mice that were immunized by the 5-week immuniz­
ation procedure to naive recipient mice, it appeared that the 
persisting parasites in immunized mice were attenuated 
(manuscript submitted for publication). In normal mice these 
parasites did no t induce cerebral malaria, while the virulent 
parent strain d id .14 Transient infections were observed when 
C57B1 and B10LP mice were inoculated in low numbers (<  103
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parasitized red blood cells/mouse), and under chemotherapeu­
tic control mice could be immunized within a  3-week period. 
The less virulent, attenuated parasites appeared to be essential 
for the induction of immunity in mice that received spleen cells 
from immune donor animals. Because of these characteristics, 
this type of parasite was called immunogenic (IP) in 
comparison to the original, more virulent, wild type (VP).
A variety of transfer models (e.g. rat and mouse) using 
parasites with self-limiting infections, attenuated parasites or 
parasites that are virulent in some, but not all, hosts has been 
reported .15" 17 A role for attenuated parasites was not 
established in any of these studies. However, the finding by 
Fahey & Spitalny15 that 7 and 14 days, but not 21 and 28 days, 
after an immunizing infection with P. yoeliU immunity could be 
transferred by spleen cells, is compatible with a role for the 
parasite in an immunizing inoculum.
This paper reports on the immunization of mice by the 
inoculation of spleen cells from P. berghei-immune donors, 
provided that the recipients were infected with IP. Transfer of 
immune spleen cells protects against IP but no t VP challenge, 
and stimulation of these immune spleen cells by live, 
proliferating IP, was essential for induction of immunity to 
the VP in recipient mice. It is shown that transferred immune 
spleen cells persisted in the recipient mice. In addition, 
development of anti-parasitic antibody appeared to be related 
to the development of immunity in the mice that received 
immune spleen cells, were boosted with IP and resisted 
challenge with VP.
M A TER IA LS AND M E T H O D S
Mice
Naive, male and female C57BL/10 or C57BL/6 J mice, used as 
recipients at 6-8  weeks old, were obtained from the central
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animal facility at the University of Nijmegen (the Netherlands). 
They were housed under specific pathogen-free conditions in 
plastic cages (39 x 22 x 14 cm) and received food (RMH, Hope 
Farms, Woerden, the Netherlands) and water ad libitum. All 
mice in any particular experiment were age-matched.
Parasites
Both the original wild type and an immunogenic form derived 
from the wild type of P. berghei K173 were used in these 
studies. The development of the immunogenic form has been 
described in detail elsewhere (manuscript submitted for 
publication). Briefly, IP were isolated on day 28 of a 5-week 
immunization procedure by the subinoculation of blood of 
mice being immunized by a chemotherapeutically controlled 
infection (see below) into splenectomized mice.
VP were kept viable by weekly passage in intact mice, and 
IP by weekly or biweekly passage in splenectomized C57BL/10 
mice using 105 parasitized red blood cells obtained via the tail 
blood of infected mice. Tail blood was collected in sterile, 
physiological saline containing 5 U heparin/ ml, adjusted to the 
appropriate concentration by determination of the percentage 
parasitaemia, and injected intraperitoneally (i.p.) into passage 
or experimental mice. The percentage parasitaemia was 
determined by counting parasitized red blood cells and 
uninfected red blood cells appearing in M ay-G riinw ald- 
Giemsa (Merck, Darmstadt, Germany)-stained thin blood 
smears.
(a) ISC VP Immune
Chemotherapeutic control o f parasite infections 
Chloroquine treatment consisted of 100 mg chloroquine base/1 
in the drinking water for a period of 5 days, and was given to 
cure an infection radically or to eliminate persisting parasites 
from immune mice.
Sulphonamide-treated mice received either 150-300 mg 
sulphathiazole Na/1 or 20-30 mg sulphadiazine/1 in their 
drinking water to suppress an infection to subpatent levels. 
Chemotherapy was stopped 2 days before a subsequent 
infection or transfer of cells.
Immunization of mice
Immunization of mice to VP by a chemotherapeutically 
controlled 5-week infection has been described elsewhere.7 
Briefly, mice were given 1-3 x 107 parasitized red blood cells. 
To prevent clinical malaria, suppressive treatment was started 
2 days after injection by the addition of sulphonamide to the 
drinking water for 33 days. Two days after withdrawal of the 
sulphonamide treatment, the mice were challenged with 105 VP 
to ascertain immunity. Mice were judged immune if para­
sitaemia did not go above 1% or stayed at or returned to 
subpatent levels. Mice with established immunity are usually 
carriers of subpatent numbers of parasites, which is called 
premunity.6,10
Adoptive transfer studies
A schematic representation of the manipulations performed in 
the final adoption of the transfer model is given in Fig. 1.
A basic format of the finally adopted transfer model is given 
in Fig. lb. Briefly, 1-4 x 107 spleen cells from immune donors 
cleared of parasites with chloroquine, were transferred 
intravenously (i.v.) to recipient mice along with IP on the 
same day. Seven days after transfer/boosting with IP, a
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Figure 1. Schematic representation of experiments to analyse the role of 
transferred immune spleen cells (ISC) and boosting by viable, 
proliferating, immunogenic parasites (IP) in the development of 
immunity to challenge by the virulent parent strain (VP). In the 
experiments described in (a-c), donor immune mice with an established 
VP immunity were chloroquine treated to eliminate subpatent 
parasitaemias immediately before collection of the spleen ceils, as 
described in the Materials and Methods.
challenge infection was given using 105 VP/mouse. Blood 
smears were made on the day of challenge with VP and at least 
once a week thereafter, for a minimum period of 4 weeks after 
the VP challenge, when mice exhibited subpatent infections, 
low transient infections or death. Spleens of immune donors 
were pooled to obtain enough of a homogeneous preparation 
for injection to all experimental mice.
Spleens and/or lymph nodes (where indicated) were 
removed from premune mice or from immune mice cleared of 
parasites after chloroquine treatment. The organs were 
dissociated by gentle pressure with a glass rod and passed 
through a sieve fitted in a 10-ml syringe containing a plug of 
cotton wool. Cells were counted in a 0*2% trypan blue/ 
physiological saline solution (diluted 1:4) on a haemo- 
cytometer (Burker-Turk, W. Schreck, Hofheim, Germany). 
Red blood cells were removed from the spleen cell suspensions 
by treatment with ammonium chloride-T ris .18 Cell 
suspensions were injected i.v. via the tail.
Mice were given immune spleen cells and IP on day 0. To 
test if and when mice had developed immunity, a challenge with 
the VP was given 5, 7, 9 or 14 days later. From  these 
experiments, the day o f challenge with the VP in the final 
model was determined (Fig. lb).
To determine the importance o f viable, proliferating IP in the 
development of VP immunity by transferred immune spleen 
cells, disrupted (freezing and thawing) parasites were injected, or 
IP infections were either left untreated, suppressed or eliminated 
by sulphonamide or chloroquine treatment (Fig. lc).
To determine if IP could stimulate protective cells in the 
recipients of immune spleen cells, mice were infected with IP, 
left untreated or given sulphonamide treatment, and 7 or 
13 days later received immune spleen cells and a challenge with 
VP (Fig. Id). Control groups were treated according to the 
basic format.
To determine the effect of boosting o f immune donors, 
immune mice received one or more challenges with 108 IP  or VP 
during the 2-week period before transfer of their spleen cells.
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The recipients of these spleen cells were subsequently 
challenged with VP (Fig. le).
A cross sex transfers
Male donor immune spleen cells are rejected by female 
recipients because o f the presence of the H-Y antigen on male 
cells.19 Using this information, immune spleen cells from either 
male or female donors were transferred to both male and 
female recipients, boosted with IP and challenged with VP 
according to the basic format. Immune spleen cells of recipients 
with an established VP immunity were collected approximately 
1 m onth after the first transfer and given to naive male and 
female recipients, again using the basic format. In this way, up 
to four subsequent transfers were performed.
Malaria-specific enzyme-linked immunosorbent assay (ELISA) 
Immunoglobulin titres to VP antigens were measured from 
plasma samples 5, 7, 10 and 14 days after infection with IP or 
VP or in recipients of immune spleen cells boosted with IP and 
challenged with VP 7 days later. Briefly, 96-well, flat-bottomed 
plates were coated with a parasite extract (100 /zl/well) prepared 
by the lysis of 307 VP/ml with 1% Triton X-100 in phosphate- 
buffered saline (PBS). Sodium azide (0*05%) was added to 
prevent bacterial contamination and the plates were stored at 
4° until use. Directly before use, plates were emptied, coated 
with 1% bovine serum albumin (CBSA)-PBS/0*1% Tween-20 
buffer (buffer A) at 100 ¿d/well and left for 1 hr. All operations 
were performed at room  temperature. Plates were then emptied 
and twofold dilutions (100 ¿d/well) of the test plasma or control 
sera (prepared from pooled immune mouse sera; IMS) were 
made in buffer A. Plates were incubated for 1 hr then washed 
with PBS, and incubated with 100//1/well of rabbit anti-mouse 
immunoglobulin peroxidase (Dakopatts, Glostrup, Denmark), 
diluted 1 :1000 in buffer A for i hr, washed with PBS and then 
incubated with tetramethylbenzidine and degassed for 20min 
before use. The reaction was stopped with 4 n  H 2SO4 and the 
extinction coefficient read at 450 nm on a Titertek Multiskan 
MCC/340, M K II reader (LC.N, Biochemical, Zoetermeer, the 
Netherlands). The titres of sera from mice with an established 
VP immunity were in the range of 1/1000 to 1/10 000. IMS was 
used as a positive reference sample in all determinations. 
Antibody titres in test samples are reported as a percentage of 
the IMS values.
R ESU LTS
The results o f typical experiments carried out to develop the 
model of induction of immunity in naive recipient mice by 
transfer of spleen cells from immune donors are summarized in 
Tables 1 to 3, and a schematic representation of these 
experiments and their outcome is given in Fig. 1. Results of 
repeated experiments were summarized. This was also done 
when small differences in the experimental set-up had no effect 
on the outcome of the experiment.
Transfer of immunity by immune spleen cells
Spleen cells from premune mice, immunized by a chemo- 
therapeutically controlled VP infection over a period of 5 
weeks, were transferred to naive recipients. Although premune
© 1995 Blackwell Science Ltd, Immunology, 85, 509-515
mice controlled their subpatent infection, the recipients of 
spleen cells from premune mice developed rapidly increasing 
infections and died. Neither control of the parasites in the 
transferred immune spleen cells nor control of additionally 
injected VP in recipients by sulphonamide treatment for a 
period of 1 week resulted in immunity to a  subsequent VP 
challenge (results not shown). When the parasites in the 
premune mice were given to normal mice by subinoculation 
of blood, parasitaemia developed similarly to that observed in 
mice infected only with the VP.
Because of these observations, in subsequent experiments 
premune mice were cured radically by chloroquine treatment 
before their spleen cells were used for transfer. When the spleen 
cells from such immune donors were transferred to recipient 
mice and these were challenged with VP directly or 7 days later, 
no protection was observed, even when low amounts o f VP 
were given (Table 1 and Fig. la). Again, a 1-week infection 
with VP controlled by sulphonamide treatment of the recipients 
did not result in immunity to VP challenge. N ot even all the 
spleen cells (the equivalent of one immune spleen) from one 
immune mouse given to one recipient mouse was able to protect 
the recipient against a VP challenge (results not shown).
When immune donors received additional challenges with 
either VP or IP in an attempt to boost the donors before 
transfer of their immune spleen cells, no protection to VP 
challenge was obtained in the recipients (Fig. le; results not 
shown). These results suggested that a direct transfer of 
immunity to VP by immune spleen cells from mice with an
• established immunity was not possible.
Immunity after transfer of immune spleen cells and boosting 
with IP
When immune spleen cells from immune donor mice, cured of 
their subpatent infection by chloroquine treatment before 
transfer, were given to naive recipients, these recipients controlled 
a challenge with IP given immediately after the transfer of the 
spleen cells (Table 1 and Fig. lb). In addition, such mice were 
immune to VP given 7 days after boosting with IP (Table 1 and 
Fig. lb), whether or not they received a suppressive treatment 
with sulphadiazine during the 7-day IP stimulation period. 
Recipients of transferred spleen cells infected with IP developed 
immunity, even when VP were present during the 1-week 
stimulation period, as long as the VP proliferation was controlled 
by sulphonamide treatment (Table 1 and Fig. lc). These results 
showed that IP immunity could be transferred by immune spleen 
cells and that boosting of recipients by IP generated protection to 
VP. Immunization by transfer of lymph node cells from immune 
donor animals and boosting in the recipient with IP was never 
successful; however, transfer of spleen cells from the same mice 
could successfully induce immunity in recipients. In  addition, 
transfer of normal spleen cells and IP boosting in the recipients, as 
well as infection with IP alone in the absence of any transferred 
cells, was unable to protect recipient mice when they were 
challenged with VP 7 days later (results not shown).
Persistence of IP for induction of immunity by transfer of 
immune spleen cells
Observing that IP boosting of immune spleen cells in recipients 
generated protection to VP, the role of IP was analysed further.
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Table 1. Protection of recipients oflSC to challenge with the virulent P. berghei parasite
Stimulation of 
ISC recipients 
(day 0)
Treatment of recipients between 
transfer of ISC and VP 
challenge (day 0-7)
VP challenge 
(day 7)
No. mice
immune
None None Yes 0/6
102VP None No 0/6
105VP Sulphadiazine Yes 0/7
104 or 106 IP None No 6/6
104 or 106 IP None Yes 14/14
105 IP Sulphadiazine Yes 8/8
10s IP and 105 VP Sulphadiazine Yes 16/16
10s VP (freeze-thawed) 
10s IP (freeze-thawed) on
None Yes 0/3
days 0, 2, 4 and 6 None Yes 0/6
10s IP Chloroquine Yes 0/6
Boosting o f recipients of immune spleen cells with freeze- 
thawed VP or IP, even with the equivalent of up to 108 VP or IP/ 
mouse every other day after transfer of immune spleen 
cells, was not able to generate VP immunity (Table 1 and 
Fig. lc). In addition, neither boosting of recipients with 108 
IP, the proliferation of which was blocked by chloroquine 
treatment starting on the day of infection (Table 1 and Fig, lc), 
nor an infection with 105 IP, which was abrogated by 
chloroquine treatment within 6 days, resulted in immune 
mice (results not shown). Thus, on the one hand untreated 
low-level IP infections or sulphonamide treatment of the IP 
infection (which suppresses proliferation but does not eliminate 
the parasites)6,10 permits the development of immunity in 
recipients of immune spleen cells, while on the other hand 
chloroquine treatment of the IP infection (which eliminates the 
parasite) or injection of freeze-thawed IP does not. This 
suggested a need for live IP for the boosting of immune 
spleen cells after transfer, and this was analysed further.
In a further series of experiments, immune spleen cells were 
transferred to recipients, and at several time-points after 
boosting with IP a VP challenge was given. When IP infection 
periods of 1 week or longer were used, immunity to VP 
developed (Table 2 and Fig. lb). From these data the basic 
format of transfer of immunity by spleen cells using IP 
infection/stimulation of recipients for a period of 7 days 
followed by VP challenge was derived (Fig. lc).
As IP boosting of recipients of immune spleen cells was 
essential, the question was raized as to whether IP infection 
alone or before the transfer of immune spleen cells prepares for
Table 2« Effect of IP proliferation period on immunity to VP challenge
in recipients of immune spleen cells
Transfer inoculum IP proliferation period
No. mice 
immune/VP challenged
ISC + 105 IP 5 days 0/3
ISC 7 days 23/26
ISC 9 days 5/5
ISC 14 days 5/5
the development of VP immunity. The results of experiments 
described in Table 3 and Fig. Id show that infection of 
recipients before transfer of immune spleen cells was not 
effective, and this was independent of sulphonamide control of 
that IP infection, while controls using the basic format became 
immune.
Results indicated an essential role of immune spleen cells 
and an infection with proliferating IP during a period of 7 days 
in the generation of immunity to VP. Consequently, the 
recipients of immune spleen cells were boosted with IP for a 
period of 7 days, followed by VP challenge to measure 
immunity.
The effect of the number of immune spleen cells and IP in the 
transfer model
Transfers using varying amounts of both immune spleen cells 
and IP in the recipients were carried out. Figure 2 shows the 
summarized data (six to 69 mice per point) from a group of 
transfer experiments using 5 x 106-1  x  108 immune spleen 
cells/mouse and 103—106 IP/mouse. The results reflected the 
percentage of mice immune to VP. It was observed that this 
increased when the number of transferred immune spleen cells 
was greater than 1 x 107. In  addition, when more IP were used 
(i.e. 104, I05 or 106 ), success rates increased to 100%, depending 
on the number of immune spleen cells. Transfers using 1 x 108 
immune spleen cells were the most successful, reaching high 
(92-100%) success rates with 104, 105 and 106 IP.
In Fig. 2, summarized data combining successful and 
less successful transfer experiments with the same number 
of immune spleen cells and IP are depicted. Thus, most 
immune mice were seen from pooled data where 1 x 108 
immune spleen cells were used, but in individual experiments 
fewer immune spleen cells could also repeatedly protect 100% 
of the mice. For practical reasons, the use of 2 -4  x 107 immune 
spleen cells and 105 IP was adopted for subsequent transfer 
experiments.
The course of infection in recipient mice in relation to transfer 
of immune spleen cells and IP boosting
Usually IP infections, either given alone or after transfer of
© 1995 Blackwell Science Ltd, Immunology, 85, 509-515
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Table 3. The effect of IP infection before or on the day of transfer of ISC on
immunity to VP challenge
Treatment between transfer of 
Day of IP infection of ISC (day 0) and VP challenge 
recipients of ISC (day 7)
No. mice 
immune/VP challenged
IP infection before transfer
Day —13 None 0/3
Day —13 Sulphonamide 0/3
Day - 7 None 0/6
Day - 7 Sulphonamide 0/6
IP infection on day of transfer
IP on day 0 None 5/5
IP on day 0 Sulphonamide 5/5
Controls
IP only, no ISC None 0/6
immune spleen cells, remained low ( < 1%) during the week 
before VP challenge. In the absence of immune spleen cells, 
IP infections continue to rise and animals died 4-6  weeks 
later. Mice given VP 7 days after IP developed a rapidly 
increasing parasitaemia and died. Mice receiving immune 
spleen cells, boosted with IP and challenged with VP 7 days 
later, frequently exhibited low-grade infections ( < i% )  
throughout; however, patency could be observed and occa­
sionally infections reached as high as 10% parasitaemia. In the 
majority of cases with elevated parasitaemias, however, 
infections returned to subpatent levels between 7 and 14 days 
after challenge with VP.
Anti-parasitic antibody and VP immunity after transfer of 
immune spleen cells boosted with IP  and challenged with VP
Anti-parasitic antibody titres in mice receiving IP, or VP, or IP 
followed by VP 7 days later, remaiiled very low, with a 
maximum of 10% of the IMS value observed in VP-immune 
mice. In recipients of immune spleen cells boosted with IP and 
challenged with VP 7 days later, antibody titres remained low 
(< 5 %  IMS value) until 7 days after transfer, and then 
increased to 15% of the IM S value on day 10 and 80% of the
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Figure 2. The percentage of mice immune to a VP challenge after 
transfer of different numbers of ISC and boosting with increasing 
numbers of IP for a period of 7 days.
IMS value on day 14 in VP-immune mice. Thus, increased anti- 
parasitic antibody levels were only observed in immune mice.
Immune spleen cells transferred from donors to same-sex or 
across-sex recipient mice.
The results of same-sex and across-sex transfers using the basic 
format showed that immunity was obtained when male 
immune spleen cells were transferred to same-sex recipients, 
or female immune spleen cells to male recipients, but transfers 
of male immune spleen cells to female recipients were 
unsuccssesful, as expected (Table 4),
To analyse further the survival and function of transferred 
immune spleen cells, female immune spleen cells were 
transferred to males, boosted with IP and challenged with 
VP. Using the same protocol, immune spleen cells o f these 
males were transferred to males again, and finally immune 
spleen cells from the second-series males were transferred back 
to females. In all of the subsequent steps, immune mice were 
obtained and, as shown in Table 4, the final transfer of immune
Table 4. The ability of immune spleen cells to transfer 
immunity to same-sex or across-sex recipient mice
Type of transfer
No. mice 
immune/VP challenged
C57B1/6J
Male-Male 7/9
Male-Female 0/9
Female-Male 9/10
Female-Female 16/16
C57B1/10
. Male-Male 9/9
Male-Female 0/9
Female-Male 10/10 .
Female-Female 7/7
Female-Male-Male 5/5
Female-Male-Male-Female 4/4
1995 Blackwell Science Ltd, Immunology, 85, 509-515
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spleen cells from males back to females was successful. As we 
have never observed successful immunization by transfer of 
immune spleen cells from male to female, these results indicated 
that the female immune spleen cells survived in the males 
during subsequent passage to the second-series males and 
finally back to the females, and were still sufficient to induce 
immunity in the female recipients after transfer in the third 
passage.
DISCUSSION
Immune spleen cells alone from mice with an established 
immunity to virulent P, berghei (VP) could not transfer 
immunity to these parasites directly. N ot even all spleen cells 
of one donor transferred to a single naive recipient could 
protect against a low dose challenge with VP. Transferred 
immune spleen cells, however, conferred protection to IP 
challenge, and boosting of immune spleen cells with IP 
generated protection to VP within a week. In addition, more 
than 107 immune spleen cells/mouse and more than 104 IP had 4 
to be given for optimal results. Additional challenges of the 
donor with IP shortly before transfer of immune spleen cells 
were not protective, suggesting that boosting the donor did not 
provide more efficient immune spleen cells and that interaction 
between IP  and immune spleen cells must take place in the 
recipient.
Only spleen cells, not lymph node cells, from immune 
donors could transfer immunity, and recipients only resisted 
VP challenge if they were stimulated by an IP infection. Neither 
an IP  nor a VP infection alone (even under sulphonamide 
control) was protective in the 1-week procedure.
The results suggest that IP have, but VP lack, essential 
information for the stimulation of immune effector cells, and 
that IP stimulation drives the immune system to protective 
reactions that subsequently control pathological reactions 
triggered by VP. Indeed, VP infections tend to trigger 
immunopathological reactions such as cerebral malaria,14 and 
IP do not (manuscript submitted for publication). In view of 
the essential role of C D 4+ T cells in development and 
maintenance of immunity in the model described here 
(manuscript submitted for publication), one hypothesis is that 
IP preferentially trigger a particular T-cell subset, the activity of 
which controls the stimulation of another subset specifically 
triggered by VP [e.g. T-helper type-2 (Th2) cells versus Thl], 
Cytokine-regulated activity of T-cell subsets20"23 and activa­
tion of T-cell subsets producing either pathology or protection 
has been described in several parasite-host combinations,24"26 
including Plasmodium infections in mice.27,28
The observations that not even chemotherapeutically 
controlled VP stimulation of immune spleen cells in recipient 
mice can induce immunity, but that either IP alone or in 
combination with VP can (Table 1), suggest that VP lack 
essential stimulatory information, which may make them a 
poor source of vaccination targets except those that aim at anti-
T O
disease protection.
Successful immunization by transfer not only depends on 
the presence of immune spleen cells and IP, but IP must 
proliferate and stimulate transferred cells for a period of 
approximately 1 week to induce VP protection (Table 1). The 
observation that extra IP challenges of donors immediately 
before transfer of immune spleen cells did not protect recipient
mice to VP challenge supports this notion. The reason why IP 
must proliferate for a period of 1 week is not clear. One 
possibility is that the immunizing principle is released by IP 
rather than being a surface molecule. Another possibility is that 
only live proliferating IP arrive at places where cells of the 
immune system can be stimulated (e.g. in the white pulp o f the 
spleen). Still another possibility is that only proliferating IP 
(not VP) can induce an essential architectural change in the 
spleen, such as like the barrier cell system described by Weiss.3
The observation that female immune spleen cells could be 
transferred to two series of male recipients and that immune 
spleen cells from the last male induced immunity in subsequent 
female recipients, suggests that the original female cells 
survived through two male passages and were still sufficient 
for subsequent transfer o f immunity to females. This supports a 
role for specifically triggered immune spleen cells in 4he 
development of protection.
In the work reported in this paper, immunity to IP, but not 
to VP, was transferred directly by immune spleen cells, which 
may suggest that only memory to IP  was present.
There was a clear association between development of 
immunity after transfer and production of anti-parasitic 
antibody. It cannot be excluded, however, that antibody 
levels parallel rather than precede development o f immunity. 
If antibody is im portant, this may indicate that Th2 activity is 
important in this model. If  protective or pathology-inducing Th 
responses can later be demonstrated, then it will be important 
to identify antigens tha t mediate these protective or patho­
logical outcomes.
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